摘要
目的探讨CK34βE12、P63和P504S在前列腺良恶性病变中的表达及鉴别诊断意义。方法应用免疫组化S-P法对57例前列腺癌及49例良性前列腺增生组织中CK34βE12、P63和P504S的表达水平及鉴别诊断意义。结果CK34βE12、P63和P504S在57例前列腺癌中的阳性表达率分别为1.7%及96.4%,P63为100%阴性表达;CK34βE12和P63在49例良性前列腺增生中阳性表达率分别为100%及100%,P504S为100%阴性表达。结论在前列腺增生性病变组织中联合检测CK34βE12、P63和P504S的表达对于前列腺良恶性病变鉴别诊断有重要意义。
Objective To study the expression and differential significance of CK34βE12, P63 and P504S in benign and malignant prostatic lesions. Methods S-P immunobistocbemical analysis was used to determine the expression levels of CK34βE12, P63 and P504S in 57cases of prostatic cancer and 49 cases of benign prostatic hyperplasia. Results The expressions of CK34βE12 and P504S in prostatic cancer was 1.7% positive and 96. 4% positive, while the expression of P63 was 100% negative; The expressions of CK34βE12 and P63 in benign prostatic hyperplasia was 100% and 100% positive, while the expression of P504S was 100% negative. Conclusion To distinguisb benign and malignant prostatic lesions, it is very significant to examine the expressions of CK34βE12, P63 and P504S combinedly in the byperplastic lesions of the prostate.
出处
《中国组织化学与细胞化学杂志》
CAS
CSCD
2008年第1期30-33,共4页
Chinese Journal of Histochemistry and Cytochemistry